Op-eds: Canadian and American regulators, law enforcement and patient advocates oppose drug importation
Since 2000, every head of the United States Food and Drug Administration (FDA) and United States Department of Health and Human Services (HHS) has opposed drug importation because the benefits that might be gained are far outweighed by the many dangers. Law enforcement, patient advocates, pharmacy groups, and regulators agree.
In this editorial, which was posted on December 2, 2020, Citizens Against Government Waste decries the expense and futility drug importation.
This editorial by Brandon Macsata was published in The International Business Times on November 1, 2020. Macsata has been living with HIV since 2002, and serves as the CEO of the ADAP Advocacy Association, an organization that promotes the AIDS Drug Assistance Program and works to improve access to care.
In this October 23, 2020 editorial, which was published in the The American Journal of Managed Care, Michael Abrams explains why drug importation will not save patients money. Abrams is the co-founder and managing partner of Numerof & Associates.
In this analysis, which was published in Lexology on October 13, 2020, three global regulatory experts examine barriers to drug importation.
In the first seven months of 2020, the Arizona Department of Health Services reported over 2,700 newly suspected opioid overdose deaths in Arizona. What makes this figure more startling is that there were just over 3,800 suspected opioid deaths in the preceding 30 months. The problem is escalating, and rapidly.
The editorial board of the Florida Times-Union published an op-ed that states that Canadian drug importation will have a limited impact, and is a sign of a broken system, not a solution to one…
In this editorial, which was published in WBUR’s Cognoscenti on September 2, 2020, writer Sarah Ruth Bates explains why Canadian drug importation is too expensive and elaborate a solution to be effective.
In this editorial, Louisiana Attorney General Jeff Landry warns parents and students about the dangers posed by counterfeit pills being sold on college campuses.
In this August 14, 2020 editorial, Best Medicines Coalition chair John Adams explains why Canadian importation will not lower U.S. medicine prices—and why the “concept of cheap drugs from Canada has never been anything more than a political hallucination.”
In this July 28, 2020 editorial published in the WasteWatcher blog, Elizabeth Wright argues that the administration’s Executive Order will “encourage more illegal behavior and a greater production of counterfeit drugs from countries like China, Mexico, and India.” Wright is the Director of Health and Public Policy for Citizens Against Government Waste